Basu Ananda, Veettil Sona, Dyer Roy, Peyser Thomas, Basu Rita
1 Endocrine Research Unit, Saint Mary's Hospital , Mayo Clinic, Rochester, Minnesota.
2 Immunochemical Core Laboratory, Mayo Clinic , Rochester, Minnesota.
Diabetes Technol Ther. 2016 Feb;18 Suppl 2(Suppl 2):S243-7. doi: 10.1089/dia.2015.0410.
Recent advances in accuracy and reliability of continuous glucose monitoring (CGM) devices have focused renewed interest on the use of such technology for therapeutic dosing of insulin without the need for independent confirmatory blood glucose meter measurements. An important issue that remains is the susceptibility of CGM devices to erroneous readings in the presence of common pharmacologic interferences. We report on a new method of assessing CGM sensor error to pharmacologic interferences using the example of oral administration of acetaminophen.
We examined the responses of several different Food and Drug Administration-approved and commercially available CGM systems (Dexcom [San Diego, CA] Seven(®) Plus™, Medtronic Diabetes [Northridge, CA] Guardian(®), and Dexcom G4(®) Platinum) to oral acetaminophen in 10 healthy volunteers without diabetes. Microdialysis catheters were placed in the abdominal subcutaneous tissue. Blood and microdialysate samples were collected periodically and analyzed for glucose and acetaminophen concentrations before and after oral ingestion of 1 g of acetaminophen. We compared the response of CGM sensors with the measured acetaminophen concentrations in the blood and interstitial fluid.
Although plasma glucose concentrations remained constant at approximately 90 mg/dL (approximately 5 mM) throughout the study, CGM glucose measurements varied between approximately 85 to 400 mg/dL (from approximately 5 to 22 mM) due to interference from the acetaminophen. The temporal profile of CGM interference followed acetaminophen concentrations measured in interstitial fluid (ISF).
This is the first direct measurement of ISF concentrations of putative CGM interferences with simultaneous measurements of CGM performance in the presence of the interferences. The observed interference with glucose measurements in the tested CGM devices coincided temporally with appearance of acetaminophen in the ISF. The method applied here can be used to determine the susceptibility of current and future CGM systems to interference from acetaminophen or other exogenous pharmacologic agents.
连续血糖监测(CGM)设备在准确性和可靠性方面的最新进展,重新引发了人们对使用该技术进行胰岛素治疗给药的兴趣,而无需独立的血糖仪测量进行确认。一个仍然存在的重要问题是,在存在常见药物干扰的情况下,CGM设备容易出现错误读数。我们以口服对乙酰氨基酚为例,报告一种评估CGM传感器对药物干扰误差的新方法。
我们在10名无糖尿病的健康志愿者中,检测了几种不同的经美国食品药品监督管理局批准且可商购的CGM系统(德康公司[加利福尼亚州圣地亚哥]的Seven(®) Plus™、美敦力糖尿病公司[加利福尼亚州北岭]的Guardian(®)以及德康G4(®) Platinum)对口服对乙酰氨基酚的反应。将微透析导管置于腹部皮下组织。在口服1克对乙酰氨基酚前后,定期采集血液和微透析液样本,并分析葡萄糖和对乙酰氨基酚浓度。我们将CGM传感器的反应与血液和间质液中测得的对乙酰氨基酚浓度进行了比较。
尽管在整个研究过程中血浆葡萄糖浓度保持在约90mg/dL(约5mM)恒定水平,但由于对乙酰氨基酚的干扰,CGM葡萄糖测量值在约85至400mg/dL(约5至22mM)之间变化。CGM干扰的时间曲线与间质液(ISF)中测得的对乙酰氨基酚浓度一致。
这是首次在存在干扰的情况下,同时测量CGM性能时,直接测量ISF中假定的CGM干扰物浓度。在测试的CGM设备中观察到的对葡萄糖测量的干扰,在时间上与对乙酰氨基酚在ISF中的出现相吻合。这里应用的方法可用于确定当前和未来CGM系统对对乙酰氨基酚或其他外源性药物干扰的敏感性。